Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-25T20:32:18.529Z Has data issue: false hasContentIssue false
  • English
  • Français

Data Acquisition for Assessment of Medical Technology: Methods Other than Technical Trials

Published online by Cambridge University Press:  10 March 2009

Lincoln E. Moses
Lincoln E. Moses
Affiliation:
Stanford University
Get access Rights & Permissions [Opens in a new window]

Extract

The term “assessment of medical technologies” does not appear to have a unique meaning that always applies to its use. It seems wise, then, to state what will be meant by the term in this chapter. “Medical technology” is regarded here as including drugs, devices, procedures, (whether preventive, diagnostic, or therapeutic) that bear more or less directly on patients. Thus, an educational program for patients might be a technology, but a training program for dietitians would not. A surgical procedure or a prosthesis would; but a scale for assessing quality of life would not. “Assessment,” as used here, refers to a complex set of activities that comprise data acquisition, analysis, and interpretation concerning properties of medical technologies. Assessment tends to be comparative, either explicitly (as to a control group) or implicitly (as looking toward “usual experience”). In any case, the goal of assessment is to increase understanding of such properties of a medical technology as its applicability, convenience, efficacy, safety, effectiveness, cost, etc.

Type
Technology Assessment: Policy, Clinical, and Methodological Issues
Information
International Journal of Technology Assessment in Health Care , Volume 2 , Issue 1 , January 1986 , pp. 27 - 38
Copyright
Copyright © Cambridge University Press 1986

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Bunker, J. P. & Blumenfeld, C. M., Liver necrosis after halothane anesthesia. New England Journal of Medicine, 1963, 268, 531–34.CrossRefGoogle ScholarPubMed
2.Bunker, J. P., Forrest, W. H. Jr, Mosteller, F., & Vandam, L. D., Eds. The national halothane study. Bethesda, Md.: National Institutes of Health, 1969.Google Scholar
3.Byar, D. P., Simon, R. M., Friedewald, W. T., Schlesselman, J. S., DeMets, D. L. et al. , Randomized clinical trials: Perspectives on some recent ideas. New England Journal of Medicine, 1976, 295, 74–80.Google Scholar
4.Cameron, E. & Campbell, A.The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplement in advanced human cancer. Chemico-Biological Interactions, 1974, 9, 285–315.Google Scholar
5.Cameron, E. & Pauling, L.Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proceedings of the National Academy of Sciences, U.S.A., 1976, 73, 3685–9.CrossRefGoogle ScholarPubMed
6.Cameron, E. & Pauling, L.Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer, Proceedings of the National Academy of Sciences, U.S.A., 1978, 75, 4538–42.CrossRefGoogle ScholarPubMed
7.Chatterjee, H. N.Control of vomiting in cholera and oral replacement of fluid. Lancet, 1953, 2, 1063.CrossRefGoogle Scholar
8.Garber, A. M., Fuchs, V. R., & Silverman, J. F., Case mix, costs and outcomes. New England Journal of Medicine, 1984, 310, 1231–37.CrossRefGoogle ScholarPubMed
9.Gehan, E. A. & Freirich, E. J.Non-randomized controls in cancer clinical trials. New England Journal of Medicine, 1974, 290, 198–203.CrossRefGoogle ScholarPubMed
10.Greenwald, P., Barlow, J. J., Nasca, P. L., & Burnett, W. S.Vaginal cancer after maternal treatment with synthetic estrogens. New England Journal of Medicine, 1971, 285, 390–92.CrossRefGoogle ScholarPubMed
11.Hammond, E. C. & Horn, D.Smoking and death rates—report on forty-four months of followup of 187, 783 men. Journal of the American Medical Association, 1958, 166, 1159–72, 1294–1308.CrossRefGoogle ScholarPubMed
12.Hewitt, D.Some features of leukemia mortality. British Journal of Preventive and Social Medicine, 1955, 9, 81–88.Google Scholar
13.Inman, W. H. W.Yellow cards and green forms. Practicioner, 1983, 227, 1443–9.Google ScholarPubMed
14.Institute of Medicine. Reliability of national hospital discharge survey data. Washington, D.C.: National Academy Press, 1980.Google Scholar
15.Lilienfeld, A. M. & Lilienfeld, D. E.Foundations of epidemiology, 2nd ed.New York, Oxford University Press, 1976.Google Scholar
16.Meier, P.Statistics and medical experimentation. Biometrics, 1975, 31, 511–30.CrossRefGoogle ScholarPubMed
17.Pocock, S. J.The combination of randomized and historical controls in clinical trials. Journal of Chronic Diseases, 1976, 29, 175–88.Google Scholar
18.Snow, J.On the inhalation of ether in surgical operations. London: John Churchill, 1847.Google Scholar
19.Stewart, A., Webb, J. & Hewitt, D.A survey of childhood malignancy. British Medical Journal, 1958, 1, 1495–1528.Google Scholar
20.Ulfelder, H.The stilbesterol disorders in historical perspective. Cancer, 1980, 45, 3008–11.3.0.CO;2-A>CrossRefGoogle Scholar
21.Underwood, E. A.Edward Jenner: the man and his work. British Medical Journal, 1949, 1, 881–84.CrossRefGoogle Scholar
22.Wittes, R. E.Vitamin C and cancer. New England Journal of Medicine, 1985, 312, 178–9.CrossRefGoogle ScholarPubMed